Atossa Wins FDA Rare Pediatric Designation, PRV Worth $100–$205M
The FDA granted Atossa Therapeutics Rare Pediatric Disease designation for (Z)-endoxifen to treat McCune-Albright Syndrome in females, making the therapy eligible for a Priority Review Voucher valued at $100–$205 million upon approval. This expands Atossa’s program into a rare pediatric endocrine disorder characterized by precocious puberty and fibrous dysplasia.
1. FDA Rare Pediatric Disease Designation
Atossa Therapeutics announced that the U.S. Food and Drug Administration has granted Rare Pediatric Disease designation to (Z)-endoxifen for treating McCune-Albright Syndrome in female patients. This designation allows Atossa to qualify for a Priority Review Voucher upon potential FDA approval of a marketing application.
2. Expansion into McCune-Albright Syndrome
McCune-Albright Syndrome is a rare genetic endocrine disorder characterized by gonadotropin-independent precocious puberty, accelerated bone maturation, fibrous dysplasia and café-au-lait skin patches. The RPD designation validates Atossa’s strategy to address this unmet pediatric need by leveraging (Z)-endoxifen’s SERM/D activity to modulate estrogen-driven disease processes.
3. Priority Review Voucher Value and Impact
Upon approval of a qualifying application, Atossa could receive a PRV that can be used for accelerated review of another drug or sold, with recent voucher sales ranging from $100–$205 million. This pathway provides a potential non-dilutive funding source that could significantly enhance Atossa’s financial outlook.